Two new glaucoma preparations in preservative-free multi-dose bottles

Eydelto (dorzolamide) and Eylamdo (dorzolamide/timolol)...

Warn patients to report visual disturbances during steroid treatment, GPs advised

Central serous chorioretinopathy (CSCR) is a retinal...

Preservative-free timolol eye drops available in multi-dose bottle

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Idebenone launched as first treatment for mitochondrial eye disease

Patients with Leber's hereditary optic neuropathy (LHON)...

Ciclosporin eye drops launched for keratitis

Increased reports of eye irritation with Xalatan

The risk of eye irritation in patients using Xalatan...

NICE recommends two treatments for diabetic macular oedema

New guidance from NICE approves the use of aflibercept...

Tafluprost/timolol now available as combined glaucoma treatment

Taptiqom is a fixed-dose combination of the prostaglandin...

News in brief - October 2014 (updated)

Other new launches, licence changes and updates relevant...

Simbrinza: new combination glaucoma treatment

Simbrinza (brinzolamide/brimonidine) is licensed for...

Neoral approved for treatment of sight-threatening uveitis

Neoral (ciclosporin) can now be used for severe refractory...

News in brief - January 2014

Other new launches, licence changes and updates relevant...

Latest approvals from the SMC

Positive opinions on Lyxumia (lixisenatide), Sayana...

News in brief - September 2013

Other new launches, licence changes and updates relevant...

NICE recommends aflibercept for AMD

New guidance from NICE approves the use of aflibercept...

New advice from the SMC

The Scottish Medicines Consortium has issued its latest...

Iluvien: intravitreal corticosteroid implant for diabetic macular oedema

Alimera has launched an intravitreal implant containing...

Jetrea: first pharmacological treatment for vitreomacular adhesion

Jetrea (ocriplasmin) is an intravitreal injection for...

Ranibizumab gains NICE approval for secondary macular oedema

Ranibizumab (Lucentis) can now be prescribed in the...